Pfizer Inc (PFE)
24.80
-1.22
(-4.69%)
USD |
NYSE |
Nov 15, 16:00
24.93
+0.13
(+0.52%)
After-Hours: 20:00
Pfizer Research and Development Expense (TTM): 10.60B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 10.60B |
| June 30, 2024 | 10.72B |
| March 31, 2024 | 10.67B |
| December 31, 2023 | 10.68B |
| September 30, 2023 | 11.48B |
| June 30, 2023 | 11.46B |
| March 31, 2023 | 11.63B |
| December 31, 2022 | 11.43B |
| September 30, 2022 | 11.26B |
| June 30, 2022 | 11.24B |
| March 31, 2022 | 10.67B |
| December 31, 2021 | 10.36B |
| September 30, 2021 | 10.26B |
| June 30, 2021 | 9.876B |
| March 31, 2021 | 9.715B |
| December 31, 2020 | 9.393B |
| September 30, 2020 | 8.608B |
| June 30, 2020 | 8.591B |
| March 31, 2020 | 8.355B |
| December 31, 2019 | 8.386B |
| September 30, 2019 | 8.039B |
| June 30, 2019 | 7.764B |
| March 31, 2019 | 7.719B |
| December 31, 2018 | 7.759B |
| September 30, 2018 | 7.864B |
| Date | Value |
|---|---|
| June 30, 2018 | 7.721B |
| March 31, 2018 | 7.711B |
| December 31, 2017 | 7.684B |
| September 30, 2017 | 7.90B |
| June 30, 2017 | 7.916B |
| March 31, 2017 | 7.877B |
| December 31, 2016 | 7.892B |
| September 30, 2016 | 7.708B |
| June 30, 2016 | 7.549B |
| March 31, 2016 | 7.535B |
| December 31, 2015 | 7.689B |
| September 30, 2015 | 8.55B |
| June 30, 2015 | 8.63B |
| March 31, 2015 | 8.655B |
| December 31, 2014 | 8.393B |
| September 30, 2014 | 6.995B |
| June 30, 2014 | 6.82B |
| March 31, 2014 | 6.591B |
| December 31, 2013 | 6.678B |
| September 30, 2013 | 6.888B |
| June 30, 2013 | 7.148B |
| March 31, 2013 | 7.218B |
| December 31, 2012 | 7.57B |
| September 30, 2012 | 7.743B |
| June 30, 2012 | 8.032B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
8.355B
Minimum
Mar 2020
11.63B
Maximum
Mar 2023
10.27B
Average
10.63B
Median
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 5.774B |
| Johnson & Johnson | 16.41B |
| Eli Lilly and Co | 10.53B |
| Merck & Co Inc | 22.98B |
| Moderna Inc | 4.827B |